Please check your internet connection and try again.
# Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep
## Overview
Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep is a combination antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. It typically contains sofosbuvir and velpatasvir.
## Primary Indications
Treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients. The specific HCV genotype and treatment history may influence regimen choice.
## Adult Dosing
The standard dose is one tablet (containing 400 mg sofosbuvir and 100 mg velpatasvir) taken orally once daily. The duration of treatment (typically 8, 12, or 16 weeks) depends on the HCV genotype, presence of cirrhosis, and prior treatment experience. Refer to current guidelines for specific recommendations.
## Pediatric Dosing
For pediatric patients weighing less than 45 kg, dosing is based on weight and is available as a fixed-dose combination tablet or granules.
* **Pediatric patients weighing 17 kg to <30 kg:** One tablet (containing 200 mg sofosbuvir and 50 mg velpatasvir) taken orally once daily for 12 weeks.
* **Pediatric patients weighing 30 kg to <45 kg:** One tablet (containing 400 mg sofosbuvir and 100 mg velpatasvir) taken orally once daily for 12 weeks.
* **Pediatric patients weighing ≥45 kg:** One tablet (containing 400 mg sofosbuvir and 100 mg velpatasvir) taken orally once daily. Treatment duration (8, 12, or 16 weeks) depends on HCV genotype and other factors.
## Dose Adjustments
No dose adjustment is required for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment; specific dosing recommendations may vary by guideline.
## Contraindications
* Hypersensitivity to sofosbuvir, velpatasvir, or any excipient.
* Concomitant use with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort), which may significantly decrease plasma concentrations of sofosbuvir and velpatasvir.
## Adverse Effects
Common adverse effects include headache, fatigue, nausea, and insomnia. More serious adverse effects are rare but can include bradycardia (especially when used with amiodarone), and potential reactivation of Hepatitis B virus (HBV) in patients with current or prior HBV infection.
## Key Drug Interactions
* **Amiodarone:** Increased risk of severe symptomatic bradycardia. Avoid concomitant use or monitor closely.
* **Strong P-gp inducers (e.g., rifampin, St. John's Wort):** Significant decrease in plasma concentrations, potentially leading to loss of efficacy. Avoid concomitant use.
* **Antacids:** Separate administration by at least 4 hours.
* **Antiretrovirals:** Some antiretrovirals may interact; consult specific drug interaction resources.
## Monitoring
* HCV RNA viral load to assess treatment response and confirm sustained virologic response (SVR) post-treatment.
* Liver function tests.
* For patients coinfected with HIV, monitor HIV viral load and CD4 count.
* Consider HBV screening prior to initiating therapy.
## Clinical Pearls
* This regimen is generally well-tolerated and highly effective across multiple HCV genotypes.
* Treatment duration is typically 8-12 weeks for treatment-naïve patients without cirrhosis, but may be extended for treatment-experienced patients or those with cirrhosis.
* Ensure patients are screened for HBV coinfection prior to therapy due to risk of HBV reactivation.
* Educate patients on the importance of adherence for optimal efficacy and to prevent resistance.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.*
